Marshall Wace, LLP Roivant Sciences Ltd. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,946,954 shares of ROIV stock, worth $31.1 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,946,954
Previous 1,441,892
104.38%
Holding current value
$31.1 Million
Previous $16.6 Million
109.52%
% of portfolio
0.04%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding ROIV
# of Institutions
338Shares Held
511MCall Options Held
813KPut Options Held
1.01M-
Qvt Financial LP New York, NY65.8MShares$695 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$655 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$505 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$466 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$374 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.44B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...